The Case Comprehensive Cancer Center seeks proposals for projects to be included in the upcoming renewal application for the current Case GI SPORE program.
All Case CCC faculty members are invited to submit project pre-proposals to compete for R01-level funding for up to five years by selection for incorporation as a full project in the GI SPORE renewal application.
All proposals must be directed towards translational research of a GI malignancy, with at least one specific aim that involves direct study of patients or of consented human tissues as defined in the SPORE RFA at: https://grants.nih.gov/grants/guide/pa-files/PAR-20-305.html.
- Proposals must include two project leaders: one Basic Science leader and one Clinical leader.
- Maximum Funding Level: $200,000/year direct costs per year (for five years)
- Proposal will include 6-page Research Strategy, biosketches for key personnel, and budget (see instructions for details).
- Successful applicants commit to submit a full 12-page proposal for further review by the GI SPORE External Advisory Board.
- Previously submitted SPORE pilot applications are welcome to be resubmitted as full projects, and may be updated with any new progress.
- An eligible SPORE Project must meet the following NCI criteria: "In each SPORE project, at least one of the following types of human endpoints should be proposed: Early phase clinical trials of new investigational drugs, biologics, experimental procedures, medical devices, or combinations; Early phase clinical trials of new combinations or new uses of Food and Drug Administration (FDA)-approved agents and devices; Discovery and development of biomarkers, only when measurements are made in human specimens, or directly in human subjects; Laboratory studies that begin with an observation in the clinic and use human specimens to generate new clinical hypotheses; Population, behavioral, or psychosocial studies, when these studies address and measure mechanistic aspects of the biology of the disease; Investigational new drug (IND)-directed toxicology studies conducted following a pre-IND meeting with the FDA in which the plan proposed by the investigators is acceptable to the FDA. Experiments using cell lines, xenografts, patient-derived xenografts (PDX), organoids, paired germline samples, or engineered tissues may be important to the translational studies proposed and are encouraged, but are not sufficient to meet the human endpoint requirement."
Applications must be submitted through InfoReady by November 15, 2020.
For questions, please contact Peggy Irwin, email@example.com.